M. Cieslik

The paper compiles and provides eight scRNA-seq datasets from nine cancer types, 174 patients, and 90,270 cancer cells to study ICB treatment responses.

The paper compares HLA-B44 peptidomes with and without tapasin to show tapasin influences C-terminal tryptophan residues and peptide binding affinity.

The paper identifies distinct mutational processes in MHC class I and II genes across primary and metastatic tumors, showing positive selection for mutations disrupting immune interfaces and linking them to immune checkpoint inhibitor response.

The paper develops a computational workflow for glyco-immunopeptidomics, identifies glycosylated MHC class II peptides, and provides a resource with over 3,400 HLA class II N-glycopeptides.

The paper identifies shared molecular features between H3K27M diffuse midline gliomas and PFA ependymomas, linking them to hindbrain developmental pathways.

The paper shows multivalent proteins rapidly phase-separate during hyperosmotic stress and reversibly dissolve upon osmotic rescue, impacting transcription termination.

This study identifies EZHIP as a PRC2 inhibitor in PFA ependymomas that mimics the H3 K27M oncohistone by disrupting PRC2 activity and H3K27me3 levels.